UNSPSC 51384523: Flurbiprofen axetil

This classification denotes a cyclooxygenase inhibitor and carbonic anhydrase inhibitor C19H19FO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier I0OU31PUI5, chemically known as (1,1'-biphenyl)-4-acetic acid, 2-fluoro-.alpha.-methyl-, 1-(acetyloxy)ethyl ester, but more generally known as flurbiprofen axetil, which bears US NIH Compound Identifier 3395. European Medicines Agency schedules Flurbiprofen axetil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02239MIG.

Most nations, for tariff and trade purposes, schedule flurbiprofen axetil under HS 29163900 and SITC 51379. As of Q4 2014, FLURBIPROFEN AXETIL remains US FDA's Preferred Term for this commodity. SMILES: CC(C1CCC(C(C1)F)C2CCCCC2)C(=O)OC(C)OC(=O)C.

UNSPSC 51384523 Flurbiprofen axetil is a Commodity code that nominally identifies a specific nonsteroidal anti-inflammatory drug, but recent state and local procurement activity under this code shows a significant mismatch. The single recent opportunity tagged to this code—Seminole County, Florida's IFB60459723LAS, posted June 30, 2026—solicits Naloxone and Safe Drug Deactivation Systems, not flurbiprofen or any pharmaceutical product consistent with the code's stated scope. The county seeks 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually, with quarterly deliveries to the Seminole County Community Health Building in Sanford. This procurement is designed to support community health initiatives and may be FEMA-funded, introducing federal compliance requirements including the Clean Air Act and Federal Water Pollution Control Act. Vendors must submit bids electronically, include all shipping and delivery costs, maintain drug-free workplace certification and E-Verify compliance, and carry workers' compensation, commercial general liability, and professional liability insurance.

The code shows minimal relevant recent activity. Seminole County, Florida is the sole issuing body represented in the available record, and the opportunity itself does not align with flurbiprofen axetil as a pharmaceutical product line. The response deadline for the Seminole County IFB was July 26, 2023, though the solicitation was posted in mid-2026 (a dating inconsistency in the source). Without additional opportunities demonstrating procurement of flurbiprofen axetil or related anti-inflammatory drugs by state and local bodies, this code does not present clear visibility into active demand. Business development professionals should verify whether the code has been misapplied in the source data or whether state and local procurement of this specific drug formulation occurs through different codes or cooperative purchasing vehicles.